Daily Cannabis Use is Associated With Lower CNS Inflammation in People With HIV

Abstract Objective: Recent cannabis exposure has been associated with lower rates of neurocognitive impairment in people with HIV (PWH). Cannabis’s anti-inflammatory properties may underlie this relationship by reducing chronic neuroinflammation in PWH. This study examined relations between cannabis use and inflammatory biomarkers in cerebrospinal fluid (CSF) and plasma, and cognitive correlates of these biomarkers within a community-based sample of PWH. Methods: 263 individuals were categorized into four groups: HIV− non-cannabis users (n = 65), HIV+ non-cannabis users (n = 105), HIV+ moderate cannabis users (n = 62), and HIV+ daily cannabis users (n = 31). Differences in pro-inflammatory biomarkers (IL-6, MCP-1/CCL2, IP-10/CXCL10, sCD14, sTNFR-II, TNF-α) by study group were determined by Kruskal–Wallis tests. Multivariable linear regressions examined relationships between biomarkers and seven cognitive domains, adjusting for age, sex/gender, race, education, and current CD4 count. Results: HIV+ daily cannabis users showed lower MCP-1 and IP-10 levels in CSF compared to HIV+ non-cannabis users (p = .015; p = .039) and were similar to HIV− non-cannabis users. Plasma biomarkers showed no differences by cannabis use. Among PWH, lower CSF MCP-1 and lower CSF IP-10 were associated with better learning performance (all ps < .05). Conclusions: Current daily cannabis use was associated with lower levels of pro-inflammatory chemokines implicated in HIV pathogenesis and these chemokines were linked to the cognitive domain of learning which is commonly impaired in PWH. Cannabinoid-related reductions of MCP-1 and IP-10, if confirmed, suggest a role for medicinal cannabis in the mitigation of persistent inflammation and cognitive impacts of HIV.

[1]  S. Peterson,et al.  Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[2]  Linda Chang,et al.  Microstructural brain abnormalities in HIV+ individuals with or without chronic marijuana use , 2020, Journal of Neuroinflammation.

[3]  G. Kinney,et al.  Self-Reported Cannabis Use and Markers of Inflammation in Men Who Have Sex With Men With and Without HIV. , 2020, Cannabis and cannabinoid research.

[4]  I. Grant,et al.  Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV. , 2020, Journal of acquired immune deficiency syndromes.

[5]  C. Costiniuk,et al.  Cannabinoids and inflammation: Implications for People Living with HIV. , 2019, AIDS.

[6]  A. Peres,et al.  Distinct inflammatory profiles in HIV-infected individuals under ART using cannabis, cocaine or cannabis plus cocaine. , 2019, AIDS.

[7]  N. Kaminski,et al.  Δ9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7–Stimulated Human Coculture , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[8]  Yanxun Xu,et al.  Sex Differences in Neurocognitive Function in Adults with HIV: Patterns, Predictors, and Mechanisms , 2019, Current Psychiatry Reports.

[9]  T. Marcotte,et al.  Plasma CXCL10 correlates with HAND in HIV-infected women , 2019, Journal of NeuroVirology.

[10]  Jessica L. Montoya,et al.  Evidence-informed practical recommendations for increasing physical activity among persons living with HIV , 2019 .

[11]  D. Jeste,et al.  Effects of Trauma, Economic Hardship, and Stress on Neurocognition and Everyday Function in HIV , 2019, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[12]  L. Fattore,et al.  The Modulating Role of Sex and Anabolic-Androgenic Steroid Hormones in Cannabinoid Sensitivity , 2018, Front. Behav. Neurosci..

[13]  A. Collier,et al.  Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy–Treated Human Immunodeficiency Virus–Infected Individuals , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Goodwin,et al.  Frequency of Cannabis Use and Medical Cannabis Use Among Persons Living With HIV in the United States: Findings From a Nationally Representative Sample. , 2018, AIDS education and prevention : official publication of the International Society for AIDS Education.

[15]  Robert M. Bilder,et al.  Effects of social adversity and HIV on subcortical shape and neurocognitive function , 2017, Brain Imaging and Behavior.

[16]  Wei‐Ju Lee,et al.  Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study , 2018, Scientific Reports.

[17]  S. Gruber,et al.  The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment , 2018, Front. Pharmacol..

[18]  M. Balíková,et al.  Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC , 2017, European Neuropsychopharmacology.

[19]  N. Kaminski,et al.  HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-&ggr;-inducible protein 10 levels compared with nonusing HIV patients , 2017, AIDS.

[20]  R. Gonzalez,et al.  Does Cannabis Use Cause Declines in Neuropsychological Functioning? A Review of Longitudinal Studies , 2017, Journal of the International Neuropsychological Society.

[21]  L. Cysique,et al.  HIV-Associated Neurocognitive Disorders: A Global Perspective , 2017, Journal of the International Neuropsychological Society.

[22]  T. Ulas,et al.  A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice , 2017, Nature Medicine.

[23]  Jie Wu,et al.  Brain cannabinoid receptor 2: expression, function and modulation , 2017, Acta Pharmacologica Sinica.

[24]  A. Burggren,et al.  Combined effects of HIV and marijuana use on neurocognitive functioning and immune status , 2016, AIDS care.

[25]  Roger N Gunn,et al.  Neuroinflammation in treated HIV-positive individuals , 2016, Neurology.

[26]  David J. Volsky,et al.  HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment , 2016, Nature Reviews Neurology.

[27]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[28]  Meng Xu,et al.  The Relationship of CSF and Plasma Cytokine Levels in HIV Infected Patients with Neurocognitive Impairment , 2015, BioMed research international.

[29]  A. Turner,et al.  Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults , 2015, Journal of Behavioral Medicine.

[30]  W. Banks,et al.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications , 2015, Brain, Behavior, and Immunity.

[31]  J. Margolick,et al.  The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation , 2015, AIDS.

[32]  S. Ramirez,et al.  Activation of Cannabinoid Type Two Receptors (CB2) Diminish Inflammatory Responses in Macrophages and Brain Endothelium , 2015, Journal of Neuroimmune Pharmacology.

[33]  Li Fei-Fei,et al.  Cannabinoid Receptor CB2 Is Involved in Tetrahydrocannabinol-Induced Anti-Inflammation against Lipopolysaccharide in MG-63 Cells , 2015, Mediators of inflammation.

[34]  Aurel Popa-Wagner,et al.  HIV-associated neurocognitive disorders , 2014, Journal of molecular psychiatry.

[35]  L. Sobell,et al.  Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. , 2014, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[36]  D. Lauffenburger,et al.  HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways , 2013, AIDS.

[37]  M. Philipp,et al.  Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain , 2013, Mediators of inflammation.

[38]  R. Ellis,et al.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection , 2013, AIDS.

[39]  Xu Wang,et al.  Attenuation of HIV‐1 replication in macrophages by cannabinoid receptor 2 agonists , 2013, Journal of leukocyte biology.

[40]  Y. Persidsky,et al.  Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation , 2013, Journal of Neuroimmune Pharmacology.

[41]  Ning Li,et al.  Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China , 2013, Journal of NeuroVirology.

[42]  M. Nagarkatti,et al.  Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator , 2012, Journal of Neuroinflammation.

[43]  J. Kornhuber,et al.  CB1 and CB2 Receptor Expression and Promoter Methylation in Patients with Cannabis Dependence , 2012, European Addiction Research.

[44]  H. Uno,et al.  Monocyte Activation Markers in Cerebrospinal Fluid Associated With Impaired Neurocognitive Testing in Advanced HIV Infection , 2012, Journal of acquired immune deficiency syndromes.

[45]  Garth E. Terry,et al.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers , 2012, Molecular Psychiatry.

[46]  S. Letendre.  Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. , 2011, Topics in antiviral medicine.

[47]  D. Meyerhoff,et al.  A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations , 2011, AIDS.

[48]  S. Thayer,et al.  Activation of Cannabinoid Type 2 Receptors Inhibits HIV-1 Envelope Glycoprotein gp120-Induced Synapse Loss , 2011, Molecular Pharmacology.

[49]  J. Leza,et al.  CCL2/MCP-1 modulation of microglial activation and proliferation , 2011, Journal of Neuroinflammation.

[50]  D. Kolson,et al.  Current understanding of HIV-associated neurocognitive disorders pathogenesis. , 2011, Current opinion in neurology.

[51]  Michael J. Taylor,et al.  Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test–Revised, Brief Visuospatial Memory Test–Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version , 2011, Journal of clinical and experimental neuropsychology.

[52]  Jia Luo,et al.  Neuronal MCP‐1 Mediates Microglia Recruitment and Neurodegeneration Induced by the Mild Impairment of Oxidative Metabolism , 2011, Brain pathology.

[53]  H. Ombao,et al.  Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning , 2011, Journal of Neuroimmunology.

[54]  E. Daar.  Faculty Opinions recommendation of HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. , 2011 .

[55]  Terry L. Jernigan,et al.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors , 2010, Journal of NeuroVirology.

[56]  T. Bisogno,et al.  Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. , 2010, CNS & neurological disorders drug targets.

[57]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[58]  M. Nagarkatti,et al.  Cannabinoids as novel anti-inflammatory drugs. , 2009, Future medicinal chemistry.

[59]  F. Vaida,et al.  Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial , 2009, Neuropsychopharmacology.

[60]  S. Kippax,et al.  Marijuana as therapy for people living with HIV/AIDS: Social and health aspects , 2007, AIDS care.

[61]  L. Chang,et al.  Combined and Independent Effects of Chronic Marijuana Use and HIV on Brain Metabolites , 2006, Journal of Neuroimmune Pharmacology.

[62]  R. Ellis,et al.  Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma , 2005, Journal of Neuroimmunology.

[63]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .

[64]  A. Holdcroft,et al.  Cannabis use in HIV for pain and other medical symptoms. , 2005, Journal of pain and symptom management.

[65]  R. Bornstein,et al.  Marijuana use and cognitive function in HIV-infected people. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[66]  Robert K. Heaton,et al.  Predictive Validity of Global Deficit Scores in Detecting Neuropsychological Impairment in HIV Infection , 2004, Journal of clinical and experimental neuropsychology.

[67]  K I Bolla,et al.  Dose-related neurocognitive effects of marijuana use , 2002, Neurology.

[68]  H. Fox,et al.  Interferon-Independent, Human Immunodeficiency Virus Type 1 gp120-Mediated Induction of CXCL10/IP-10 Gene Expression by Astrocytes In Vivo and In Vitro , 2001, Journal of Virology.

[69]  J. Weiss,et al.  Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. , 1998, Journal of immunology.

[70]  S. Letendre,et al.  Beneficial Effects of Cannabis on Blood–Brain Barrier Function in Human Immunodeficiency Virus , 2021 .

[71]  S. Woods,et al.  Real-World Impact of HIV-Associated Neurocognitive Impairment , 2017 .

[72]  P. Tien,et al.  Monocyte Activation Is Associated With Worse Cognitive Performance in HIV-Infected Women With Virologic Suppression , 2017, The Journal of infectious diseases.

[73]  Timothy J. Williamson,et al.  Marijuana effects on changes in brain structure and cognitive function among HIV+ and HIV- adults. , 2017, Drug and alcohol dependence.

[74]  M. Huestis,et al.  Human Cannabinoid Pharmacokinetics and Interpretation of Cannabinoid Concentrations in Biological Fluids and Tissues , 2007 .